Biological evaluation and molecular modelling study of thiosemicarbazide derivatives as bacterial type IIA topoisomerases inhibitors

被引:22
作者
Paneth, Agata [1 ,5 ]
Staczek, Pawel [2 ]
Plech, Tomasz [1 ]
Strzelczyk, Aleksandra [2 ]
Dzitko, Katarzyna [3 ]
Wujec, Monika [1 ]
Kusmierz, Edyta [1 ]
Kosikowska, Urszula [4 ]
Grzegorczyk, Agnieszka [4 ]
Paneth, Piotr [5 ]
机构
[1] Med Univ Lublin, Dept Organ Chem, Lublin, Poland
[2] Univ Lodz, Dept Microbial Genet, PL-90131 Lodz, Poland
[3] Univ Lodz, Dept Immunoparasitol, PL-90131 Lodz, Poland
[4] Med Univ Lublin, Dept Pharmaceut Microbiol, Lublin, Poland
[5] Lodz Univ Technol, Inst Appl Radiat Chem, Lodz, Poland
关键词
Antibacterials; bacterial type IIA topoisomerases; molecular modelling; thiosemicarbazide derivatives; toxicity; INFECTIOUS-DISEASES SOCIETY; GRAM-NEGATIVE BACILLI; DNA GYRASE; STAPHYLOCOCCUS-AUREUS; BAD BUGS; ANTIBACTERIAL; VANCOMYCIN; RESISTANCE; IV; DRUGS;
D O I
10.3109/14756366.2014.1003214
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In the present article, we describe the inhibitory potency of nine thiosemicarbazide derivatives against bacterial type IIA topoisomerases, their antibacterial profile and molecular modelling evaluation. We found that one of the tested compounds, compound 7, significantly inhibits activity of Staphylococcus aureus DNA gyrase with an IC50 below 15 mu M. Besides, this compound displays antibacterial activity on reference Staphylococuss spp. and Enterococcus faecalis strains as well as clinical S. aureus isolates at non-cytotoxic concentrations in mammalian cells with MIC values ranging from 16 to 32 mu g/mL thereby indicating, in some cases, equipotent or even more effective action than standard drugs such as vancomycin, ampicillin and nitrofurantoin. The computational studies showed that both molecular geometry and the electron density distribution have a great impact on antibacterial activity of thiosemicarbazide derivatives.
引用
收藏
页码:14 / 22
页数:9
相关论文
共 43 条
[1]   Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit [J].
Albanèse, J ;
Léone, M ;
Bruguerolle, B ;
Ayem, ML ;
Lacarelle, B ;
Martin, C .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (05) :1356-1358
[2]  
[Anonymous], ANN REP EUR ANT RES
[3]  
[Anonymous], 2002, PUBLIC HLTH REP
[4]  
[Anonymous], 2006, M2A9 CLIN LAB STAND
[5]   Type IIA topoisomerase inhibition by a new class of antibacterial agents [J].
Bax, Benjamin D. ;
Chan, Pan F. ;
Eggleston, Drake S. ;
Fosberry, Andrew ;
Gentry, Daniel R. ;
Gorrec, Fabrice ;
Giordano, Ilaria ;
Hann, Michael M. ;
Hennessy, Alan ;
Hibbs, Martin ;
Huang, Jianzhong ;
Jones, Emma ;
Jones, Jo ;
Brown, Kristin Koretke ;
Lewis, Ceri J. ;
May, Earl W. ;
Saunders, Martin R. ;
Singh, Onkar ;
Spitzfaden, Claus E. ;
Shen, Carol ;
Shillings, Anthony ;
Theobald, Andrew J. ;
Wohlkonig, Alexandre ;
Pearson, Neil D. ;
Gwynn, Michael N. .
NATURE, 2010, 466 (7309) :935-U51
[6]   The Newer Fluoroquinolones [J].
Bolon, Maureen K. .
MEDICAL CLINICS OF NORTH AMERICA, 2011, 95 (04) :793-+
[7]   10 x '20 Progress-Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of America [J].
Boucher, Helen W. ;
Talbot, George H. ;
Benjamin, Daniel K., Jr. ;
Bradley, John ;
Guidos, Robert J. ;
Jones, Ronald N. ;
Murray, Barbara E. ;
Bonomo, Robert A. ;
Gilbert, David .
CLINICAL INFECTIOUS DISEASES, 2013, 56 (12) :1685-1694
[8]   Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America [J].
Boucher, Helen W. ;
Talbot, George H. ;
Bradley, John S. ;
Edwards, John E., Jr. ;
Gilbert, David ;
Rice, Louis B. ;
Scheld, Michael ;
Spellberg, Brad ;
Bartlett, John .
CLINICAL INFECTIOUS DISEASES, 2009, 48 (01) :1-12
[9]   Antibiotics in the clinical pipeline in 2011 [J].
Butler, Mark S. ;
Cooper, Matthew A. .
JOURNAL OF ANTIBIOTICS, 2011, 64 (06) :413-425
[10]  
Clinical and Laboratory Standards Institute, 2006, METH DIL ANT SUSC TE, V7